Clinical Trials Logo

Thymic Cancer clinical trials

View clinical trials related to Thymic Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT03219554 Not yet recruiting - Thymic Cancer Clinical Trials

A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor

Start date: August 2017
Phase: Phase 2
Study type: Interventional

This is a phase II single center, open-label, single arm study of palbociclib treatment in patients with recurrent or metastatic advanced TETs after failure of one or more cytotoxic chemotherapy regimens. Patients will receive oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.